about
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort studySafety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trialChildhood pneumonia and crowding, bed-sharing and nutrition: a case-control study from The GambiaCase-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controlsCase-control vaccine effectiveness studies: Data collection, analysis and reporting resultsChapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries.Sustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective.Epidemiological studies of the 'non-specific effects' of vaccines: I--data collection in observational studies.Comparison of rapid tests for detection of rifampicin-resistant Mycobacterium tuberculosis in Kampala, Uganda.Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, UgandaPlacebo use in vaccine trials: recommendations of a WHO expert panelThe Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field.Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.Selection and quantification of infection endpoints for trials of vaccines against intestinal helminthsThe impact of childhood vaccines on bacterial carriage in the nasopharynx: a longitudinal study.Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study.Setting research priorities to improve global newborn health and prevent stillbirths by 2025.Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis.Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak.A guide for diagnostic evaluations.A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings.Clinical trials to estimate the efficacy of preventive interventions against malaria in paediatric populations: a methodological review.First generation leishmaniasis vaccines: a review of field efficacy trials.Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection.Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis.Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultationProtection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials.Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, UgandaWHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.A case-control study of sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of clustering.A guide for diagnostic evaluations.Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.The duration of protection of school-aged BCG vaccination in England: a population -based case-control study.MALVAC 2008: Measures of efficacy of malaria vaccines in phase 2b and phase 3 trials--scientific, regulatory and public health perspectives.WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.Assessment of the RTS,S/AS01 malaria vaccine.Scale-up of antiretroviral therapy in sub-Saharan Africa: priorities for public health research.Considerations for using ETEC and Shigella disease burden estimates to guide vaccine development strategy.
P50
Q28477435-1611FCA4-0C59-471F-BFDF-743CB94207DEQ28538775-D49424F9-ABE7-4E4B-8D0B-15330949EFC1Q28595927-63877700-1BC6-44D6-AA69-4786AF952EF6Q29994559-974B6CBA-7E73-4AAB-B033-660CDD6FBA76Q29994560-F2F8BFDD-BB84-4E0D-90A7-0230DBA93310Q30230410-9763D227-D351-40E9-A4DB-AE8AAF6B44C5Q30396940-675AC81A-F066-456E-ADE8-CB77BA7DA0C8Q33468618-1C08019B-B26E-4EED-9CD2-2C9AB4BA8A50Q33497027-93167F33-3726-42E1-84CC-A1A0F11ADB85Q33904830-53CB0893-3EC7-4650-942A-173C9798531FQ34147558-D1FB3AE8-922C-46C3-904C-2989724304EFQ34489055-0643A380-E177-4638-9F86-9E4B931D16F7Q34704669-C9FC4CA4-49A3-4606-954A-D53353DF29D4Q34978256-FCF2F726-112B-45D4-8A09-CFAF75956BC6Q35033974-8051B5E0-73E7-4EF8-A303-2B82B45A3C5DQ35114820-8B530994-30FD-4D2D-BAFB-6F07E0D167F7Q35786265-0DA0880E-424A-4C37-A192-CEB49334D81FQ36238223-164778E6-330E-42EC-BAB8-0203AE42C225Q36536012-31A1FF2C-F2B4-494C-91BD-F40D87EBE93BQ36604931-2DE9172F-B353-40AE-8F5B-27718FA40342Q36914863-3BCB9B7A-CA93-47EB-BE53-BDB999314CA9Q37107195-786D64D6-17E3-4C76-96E8-4211696EBDC5Q37308029-36DE6506-41CF-4674-AE07-0ED71A060770Q37352530-C054B6EA-F244-4232-891D-1F01C603213FQ37525093-60BAB607-427A-406F-9D02-5C97906E96AEQ37706823-D923DD23-DB29-4BA1-A382-AF4C9DB9C2FCQ38171263-6E7D7EFB-DFA8-4F91-A980-7A74F9FEC425Q38664853-A4CD55AE-4ADB-4E27-B489-78F434BD0F52Q38878637-ED3CECC1-2A3A-4113-BE70-6E3DD2A68862Q39142507-CCB69045-84CF-49D9-8013-EA28F4D6FB3AQ39182406-F22A0D42-823C-4ADC-8902-386AE267654FQ39346313-154A9F17-7587-434F-9C37-007CCE558871Q39550507-9D44058E-ED7C-4624-876F-939C7AC07AB7Q40039507-30C9BC14-5A3B-417D-9047-AE9B22995DCAQ41986442-F779FBA3-EB70-4B87-A1DE-6892313584C8Q42605516-BA52B52D-1209-441C-ADEC-F68C73FF2951Q45341636-408091BF-F0D1-487E-94F3-8A57B4895DA1Q45785252-84E59255-265E-4757-AEC6-28472A12AB4AQ46383170-C2B26897-525B-4234-ADA7-E1D8B7D0E701Q47795634-8BA35027-288B-48A8-9F7C-EE900A2379C0
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Peter G Smith
@ast
Peter G Smith
@en
Peter G Smith
@es
Peter G Smith
@nl
Peter G Smith
@sl
type
label
Peter G Smith
@ast
Peter G Smith
@en
Peter G Smith
@es
Peter G Smith
@nl
Peter G Smith
@sl
altLabel
Peter G Smith
@en
prefLabel
Peter G Smith
@ast
Peter G Smith
@en
Peter G Smith
@es
Peter G Smith
@nl
Peter G Smith
@sl
P106
P21
P214
3768148753691141320000
P31
P496
0000-0003-0080-7560
P734
P735
P7859
viaf-3768148753691141320000